BE2013C063I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2013C063I2 BE2013C063I2 BE2013C063C BE2013C063C BE2013C063I2 BE 2013C063 I2 BE2013C063 I2 BE 2013C063I2 BE 2013C063 C BE2013C063 C BE 2013C063C BE 2013C063 C BE2013C063 C BE 2013C063C BE 2013C063 I2 BE2013C063 I2 BE 2013C063I2
- Authority
- BE
- Belgium
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002336843 | 2002-11-20 | ||
| JP2003065807 | 2003-03-11 | ||
| JP2003139616 | 2003-05-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE2013C063I2 true BE2013C063I2 (ja) | 2023-03-07 |
Family
ID=32329647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2013C063C BE2013C063I2 (ja) | 2002-11-20 | 2013-11-14 |
Country Status (31)
| Country | Link |
|---|---|
| US (6) | US7176220B2 (ja) |
| EP (5) | EP2161258A3 (ja) |
| KR (1) | KR100665919B1 (ja) |
| AR (2) | AR042095A1 (ja) |
| AT (1) | ATE443048T1 (ja) |
| AU (1) | AU2003302029B8 (ja) |
| BE (1) | BE2013C063I2 (ja) |
| BR (1) | BRPI0306214B1 (ja) |
| CA (1) | CA2470365C (ja) |
| CY (2) | CY1110690T1 (ja) |
| CZ (1) | CZ2004764A3 (ja) |
| DE (1) | DE60329318D1 (ja) |
| DK (1) | DK1564210T5 (ja) |
| ES (1) | ES2329240T3 (ja) |
| FR (1) | FR13C0061I2 (ja) |
| HU (1) | HUS1300066I1 (ja) |
| IL (2) | IL162548A0 (ja) |
| LT (1) | LTPA2013018I1 (ja) |
| LU (1) | LU92307I2 (ja) |
| MX (1) | MXPA04006553A (ja) |
| MY (1) | MY136173A (ja) |
| NO (3) | NO327098B1 (ja) |
| NZ (1) | NZ533641A (ja) |
| PE (1) | PE20040840A1 (ja) |
| PT (1) | PT1564210E (ja) |
| SI (1) | SI1564210T1 (ja) |
| SK (1) | SK2662004A3 (ja) |
| TR (1) | TR200401663T1 (ja) |
| TW (1) | TWI248928B (ja) |
| WO (1) | WO2004046115A1 (ja) |
| ZA (1) | ZA200404537B (ja) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ533057A (en) | 2001-10-26 | 2005-11-25 | Angeletti P Ist Richerche Bio | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
| EP2161258A3 (en) * | 2002-11-20 | 2010-04-07 | Japan Tabacco Inc. | 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
| DE602005023717D1 (de) | 2004-03-10 | 2010-11-04 | Usa | Chinolin-4-one als inhibitoren der retroviralen integrase zur behandlung von hiv, aids und aids-related complex (arc) |
| MY134672A (en) * | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
| WO2005113509A1 (en) * | 2004-05-20 | 2005-12-01 | Japan Tobacco Inc. | Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
| EP3287130A1 (en) * | 2004-05-21 | 2018-02-28 | Japan Tobacco Inc. | Combinations comprising a 4-isoquinolone derivative and protease inhibitors |
| WO2006033422A1 (ja) * | 2004-09-21 | 2006-03-30 | Japan Tobacco Inc. | キノリジノン化合物、およびそのｈｉｖインテグラーゼ阻害剤としての利用 |
| US7745459B2 (en) * | 2004-09-21 | 2010-06-29 | Japan Tobacco Inc. | Quinolizinone compound and use thereof as HIV integrase inhibitor |
| UA87884C2 (uk) * | 2004-12-03 | 2009-08-25 | Мерк Энд Ко., Инк. | Безводна кристалічна калієва сіль інгібітора віл-інтегрази |
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| US20070032522A1 (en) * | 2005-07-01 | 2007-02-08 | Kumar Dange V | Antiviral agents |
| WO2007063869A1 (ja) * | 2005-11-30 | 2007-06-07 | Japan Tobacco Inc. | 高純度キノロン化合物の製造方法 |
| JP4676536B2 (ja) * | 2005-12-30 | 2011-04-27 | ギリアド サイエンシズ， インコーポレイテッド | Ｈｉｖインテグラーゼ阻害剤の薬物動態の改善方法 |
| AU2013203476C1 (en) * | 2005-12-30 | 2016-11-17 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
| US20090233964A1 (en) * | 2005-12-30 | 2009-09-17 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
| JP2009525261A (ja) * | 2006-02-01 | 2009-07-09 | 日本たばこ産業株式会社 | レトロウイルス感染症の治療のための、６−（３−クロロ−２−フルオロベンジル）−１−［（２ｓ）−１−ヒドロキシ−３−メチルブタン−２−イル］−７−メトキシ−４−オキソ−１，４−ジヒドロキノリン−３−カルボン酸またはその塩の使用 |
| WO2007092802A1 (en) * | 2006-02-09 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Method for treating hiv infection through co-administration of tipranavir and gs 9137 |
| RS54047B1 (sr) * | 2006-03-06 | 2015-10-30 | Japan Tobacco Inc. | Postupak za dobijanje jedinjenja 4-oksohinolina |
| IN2014CN00532A (ja) * | 2006-03-06 | 2015-04-03 | Japan Tobacco Inc | |
| PE20080697A1 (es) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
| TW200811153A (en) * | 2006-06-23 | 2008-03-01 | Japan Tobacco Inc | 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor |
| RU2399616C1 (ru) * | 2006-06-23 | 2010-09-20 | Джапан Тобакко Инк. | Производное 6-(гетероциклзамещенный бензил)-4-оксохинолина и его применение в качестве ингибитора интегразы вич |
| SG183007A1 (en) | 2006-07-07 | 2012-08-30 | Gilead Sciences Inc | Modulators of pharmacokinetic properties of therapeutics |
| EP2046328A4 (en) | 2006-07-19 | 2009-10-28 | Univ Georgia Res Found | PYRIDINONE DIKETOIC ACIDS: INHIBITORS OF HIV REPLICATION IN COMBINATION THERAPY |
| EA022099B1 (ru) | 2006-09-12 | 2015-11-30 | Джилид Сайэнс, Инк. | Способы и интермедиаты для получения ингибиторов интегразы |
| KR20090077813A (ko) | 2006-09-29 | 2009-07-15 | 아이데닉스 파마슈티칼스, 인코포레이티드 | Ｈｉｖ 억제제로서의 거울상이성질체적으로 순수한 포스포인돌 |
| KR20090097194A (ko) | 2006-12-22 | 2009-09-15 | 아벡사 리미티드 | 바이사이클 피리미디논 및 그 용도 |
| PL3150586T3 (pl) | 2007-02-23 | 2020-06-01 | Gilead Sciences, Inc. | Modulatory farmakokinetycznych właściwości środków terapeutycznych |
| WO2009006199A1 (en) * | 2007-06-29 | 2009-01-08 | Gilead Sciences, Inc. | Therapeutic compositions and the use thereof |
| AR067184A1 (es) * | 2007-06-29 | 2009-09-30 | Gilead Sciences Inc | Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica |
| PE20090938A1 (es) | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
| AR068403A1 (es) * | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
| MX2010002679A (es) * | 2007-09-12 | 2010-03-29 | Concert Pharmaceuticals Inc | Derivados de 4-oxoquinolina deuterados para el tratamiento de la infeccion por el virus de inmunodeficiencia humana. |
| CA2705318C (en) * | 2007-11-15 | 2013-12-31 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| MX2010005334A (es) | 2007-11-16 | 2010-05-27 | Boehringer Ingelheim Int | Inhibidores de la replicacion del virus de la inmunodeficiencia humana. |
| JP2011517313A (ja) | 2007-12-11 | 2011-06-02 | ビアメト ファーマシューティカルズ，インク． | 金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤 |
| WO2009089263A2 (en) * | 2008-01-07 | 2009-07-16 | Ardea Biosciences Inc. | Novel compositions and methods of use |
| HRP20151357T1 (hr) | 2008-05-02 | 2016-01-29 | Gilead Sciences, Inc. | Upotreba äśestica äśvrstog nosaäśa kako bi se poboljšala procesabilnost farmaceutskog agensa |
| WO2010073078A2 (en) * | 2008-12-22 | 2010-07-01 | Orchid Research Laboratories Ltd. | Heterocyclic compounds as hdac inhibitors |
| DK2393485T3 (en) | 2009-02-06 | 2015-10-26 | Gilead Sciences Inc | Bilayer COVERING ELVITEGRAVIR, COBICISTAT, emtricitabine and tenofovir |
| AP2011005795A0 (en) | 2009-02-13 | 2011-08-31 | Boehringer Ingelheim Int | SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia. |
| BRPI1008560B1 (pt) | 2009-02-13 | 2021-08-31 | Boehringer Ingelheim International Gmbh | Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dpp-iv e opcionalmente um outro agente antidiabético e usos dos mesmos |
| WO2010137032A2 (en) * | 2009-05-14 | 2010-12-02 | Matrix Laboratories Ltd. | Novel polymorphic forms of elvitegravir and its pharmaceutically acceptable salts |
| WO2011004389A2 (en) | 2009-06-18 | 2011-01-13 | Matrix Laboratories Ltd | An improved process for the preparation of elvitegravir |
| WO2011025683A1 (en) * | 2009-08-26 | 2011-03-03 | Merck Sharp & Dohme Corp. | Hiv integrase inhibitors |
| JP5758900B2 (ja) | 2009-09-30 | 2015-08-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グルコピラノシル置換ベンジルベンゼン誘導体の調製方法 |
| AU2010303123B2 (en) | 2009-09-30 | 2014-02-27 | Boehringer Ingelheim International Gmbh | Method for the preparation of a crystalline form of 1-chloro-4- (Beta-D-glucopyranos-1-yl)-2-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)benzene |
| UY32919A (es) | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos |
| WO2011045330A1 (en) | 2009-10-13 | 2011-04-21 | Tibotec Pharmaceuticals | Macrocyclic integrase inhibitors |
| WO2011071849A2 (en) | 2009-12-07 | 2011-06-16 | University Of Georgia Research Foundation, Inc. | Pyridinone hydroxycyclopentyl carboxamides: hiv integrase inhibitors with therapeutic applications |
| RU2567385C2 (ru) | 2010-04-02 | 2015-11-10 | ЯНССЕН Ар ЭНД Ди АЙРЛЭНД | Макроциклические ингибиторы интегразы |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| KR20130124291A (ko) | 2010-07-02 | 2013-11-13 | 길리애드 사이언시즈, 인코포레이티드 | Ｈｉｖ 항바이러스 화합물로서의 2-퀴놀리닐-아세트산 유도체 |
| AP2013006706A0 (en) | 2010-07-02 | 2013-02-28 | Gilead Sciences Inc | Napht-2-ylacetic acid derivatives to treat AIDS |
| AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
| BR112013027096A2 (pt) | 2011-04-21 | 2016-12-27 | Gilead Sciences Inc | compostos de benzotiazol e seu uso farmacêutico |
| WO2013103724A1 (en) | 2012-01-04 | 2013-07-11 | Gilead Sciences, Inc. | 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids |
| US9284323B2 (en) | 2012-01-04 | 2016-03-15 | Gilead Sciences, Inc. | Naphthalene acetic acid derivatives against HIV infection |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| ES2571479T3 (es) | 2012-04-20 | 2016-05-25 | Gilead Sciences Inc | Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH |
| CA2878699C (en) | 2012-08-03 | 2018-09-11 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
| CZ304983B6 (cs) | 2012-10-12 | 2015-03-11 | Zentiva, K.S. | Způsob výroby a nové intermediáty syntézy elvitegraviru |
| CZ304984B6 (cs) | 2012-10-12 | 2015-03-11 | Zentiva, K.S. | Zlepšený způsob výroby a nové intermediáty syntézy elvitegraviru |
| EA030003B1 (ru) | 2012-12-21 | 2018-06-29 | Джилид Сайэнс, Инк. | Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции |
| PL2938185T3 (pl) | 2012-12-26 | 2020-11-02 | Société des Produits Nestlé S.A. | Kompozycje powlekanego żwirku dla zwierząt o niskiej gęstości |
| CA2812519A1 (en) | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| HRP20190101T1 (hr) | 2013-04-05 | 2019-03-08 | Boehringer Ingelheim International Gmbh | Terapeutske uporabe empagliflozina |
| FI4000608T3 (fi) | 2013-04-18 | 2026-01-21 | Boehringer Ingelheim Int | Farmaseuttinen koostumus, menetelmä hoitamiseksi ja sen käyttöjä |
| CZ307255B6 (cs) * | 2013-07-11 | 2018-05-02 | Zentiva, K.S. | Nový způsob přípravy elvitegraviru |
| SI3019503T1 (sl) | 2013-07-12 | 2017-11-30 | Gilead Sciences, Inc. | Policiklične karbamoilpiridonske spojine in njihova uporaba za zdravljenje HIV infekcij |
| NO2865735T3 (ja) | 2013-07-12 | 2018-07-21 | ||
| TWI677489B (zh) | 2014-06-20 | 2019-11-21 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| NO2717902T3 (ja) | 2014-06-20 | 2018-06-23 | ||
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| CN107406390B (zh) | 2014-11-17 | 2021-04-16 | 奈吉治疗公司 | 单羧酸转运蛋白调节剂及其用途 |
| TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| JP6402259B2 (ja) | 2015-04-02 | 2018-10-10 | ギリアード サイエンシーズ， インコーポレイテッド | 多環式カルバモイルピリドン化合物およびそれらの薬学的使用 |
| WO2016193997A2 (en) * | 2015-06-03 | 2016-12-08 | Msn Laboratories Private Limited | Process for the preparation of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and pharmaceutically acceptable salts thereof |
| ES2925000T3 (es) | 2015-10-23 | 2022-10-13 | Nestle Sa | Arenas higiénicas para mascotas de baja densidad y métodos de elaboración de tales arenas higiénicas para mascotas |
| RU2654062C2 (ru) * | 2016-07-14 | 2018-05-16 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Производные хиназолин-4(3н)-она, ингибирующие натрий-водородный обмен |
| KR20250097990A (ko) | 2016-11-10 | 2025-06-30 | 베링거 인겔하임 인터내셔날 게엠베하 | 약제학적 조성물, 치료 방법 및 이의 용도 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3472859A (en) * | 1966-11-01 | 1969-10-14 | Sterling Drug Inc | 1-alkyl-1,4-dihydro-4-oxo-3 quinoline-carboxylic acids and esters |
| JPS4826772A (ja) | 1971-08-11 | 1973-04-09 | ||
| DE3501247A1 (de) * | 1985-01-16 | 1986-07-17 | Bayer Ag, 5090 Leverkusen | Aminoacrylsaeure-derivate |
| US5563138A (en) * | 1987-04-16 | 1996-10-08 | Otsuka Pharmaceutical Company, Limited | Benzoheterocyclic compounds |
| EP0319906A3 (en) * | 1987-12-11 | 1990-05-02 | Dainippon Pharmaceutical Co., Ltd. | Novel quinoline derivatives, processes for preparation thereof and antibacterial agent containing them |
| US4920120A (en) * | 1988-01-25 | 1990-04-24 | Warner-Lambert Company | Antibacterial agents |
| DE3934082A1 (de) * | 1989-10-12 | 1991-04-18 | Bayer Ag | Chinoloncarbonsaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung als antivirale mittel |
| DE4015299A1 (de) * | 1990-05-12 | 1991-11-14 | Bayer Ag | Verfahren zur herstellung von 3-amino-2-(het)-aroyl-acrylsaeurederivaten |
| IL100555A (en) | 1991-02-07 | 2000-08-31 | Hoechst Marion Roussel Inc | N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them |
| NO304832B1 (no) | 1992-05-27 | 1999-02-22 | Ube Industries | Aminokinolonderivater samt middel mot HIV |
| JP2993316B2 (ja) | 1992-05-27 | 1999-12-20 | 宇部興産株式会社 | アリール基又は複素芳香環基置換アミノキノロン誘導体及びエイズ治療剤 |
| JPH06199635A (ja) | 1992-12-28 | 1994-07-19 | Kanebo Ltd | 化粧料 |
| JPH06199835A (ja) | 1993-01-08 | 1994-07-19 | Hokuriku Seiyaku Co Ltd | ８−ジフルオロメトキシキノリン−３−カルボン酸誘導体 |
| JPH06271568A (ja) | 1993-03-22 | 1994-09-27 | Hokuriku Seiyaku Co Ltd | ７−フェニルピペラジニルキノリン−３−カルボン酸誘導体 |
| WO1995029891A1 (en) | 1994-04-28 | 1995-11-09 | Yamanouchi Pharmaceutical Co., Ltd. | N-(3-pyrrolidinyl)benzamide derivative |
| JP2930539B2 (ja) | 1994-07-18 | 1999-08-03 | 三共株式会社 | トリフルオロメチルキノリンカルボン酸誘導体 |
| MX9700497A (es) * | 1994-07-18 | 1997-04-30 | Ube Industries | Derivado de acido trifluorometilquinolinocarboxilico. |
| JPH08183776A (ja) | 1994-12-28 | 1996-07-16 | Hideaki Yamaguchi | 金属の表面保護剤ならびにそれを用いた製造方法 |
| US6303611B1 (en) * | 1996-03-08 | 2001-10-16 | Adolor Corporation | Kappa agonist compounds and pharmaceutical formulations thereof |
| JP4121151B2 (ja) | 1996-04-12 | 2008-07-23 | アメリカ合衆国 | 抗新生物薬および抗レトロウイルス薬として有用なアクリドンから誘導された化合物 |
| US6287550B1 (en) * | 1996-12-17 | 2001-09-11 | The Procter & Gamble Company | Animal care system and litter with reduced malodor impression |
| US5989451A (en) | 1997-02-07 | 1999-11-23 | Queen's University At Kingston | Compounds and methods for doping liquid crystal hosts |
| FR2761687B1 (fr) * | 1997-04-08 | 2000-09-15 | Centre Nat Rech Scient | Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques |
| JP3776203B2 (ja) | 1997-05-13 | 2006-05-17 | 第一製薬株式会社 | Ｉｃａｍ−１産生阻害剤 |
| KR20010013377A (ko) * | 1997-06-04 | 2001-02-26 | 데이비드 엠 모이어 | 마일드한 잔류성 항균 조성물 |
| TW527355B (en) | 1997-07-02 | 2003-04-11 | Bristol Myers Squibb Co | Inhibitors of farnesyl protein transferase |
| JPH1184556A (ja) | 1997-09-08 | 1999-03-26 | Konica Corp | ハロゲン化銀乳剤、該乳剤を用いる感光材料の処理方法及び撮影方法 |
| GB9721964D0 (en) | 1997-10-16 | 1997-12-17 | Pfizer Ltd | Isoquinolines |
| GB9807903D0 (en) | 1998-04-14 | 1998-06-10 | Smithkline Beecham Plc | Novel compounds |
| US6399629B1 (en) * | 1998-06-01 | 2002-06-04 | Microcide Pharmaceuticals, Inc. | Efflux pump inhibitors |
| US6248736B1 (en) | 1999-01-08 | 2001-06-19 | Pharmacia & Upjohn Company | 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents |
| US6248739B1 (en) | 1999-01-08 | 2001-06-19 | Pharmacia & Upjohn Company | Quinolinecarboxamides as antiviral agents |
| FR2795726A1 (fr) | 1999-06-30 | 2001-01-05 | Aventis Cropscience Sa | Nouveaux pyrazoles fongicides |
| DE19950898A1 (de) * | 1999-10-22 | 2001-04-26 | Aventis Pharma Gmbh | Heterocyclisch substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| PE20011349A1 (es) | 2000-06-16 | 2002-01-19 | Upjohn Co | 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales |
| US6730682B2 (en) | 2000-07-12 | 2004-05-04 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
| US6559145B2 (en) | 2000-07-12 | 2003-05-06 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
| JP2004513134A (ja) | 2000-10-12 | 2004-04-30 | メルク エンド カムパニー インコーポレーテッド | Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルケトン類 |
| JP2004517860A (ja) | 2000-10-12 | 2004-06-17 | メルク エンド カムパニー インコーポレーテッド | Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類 |
| HUP0303991A3 (en) * | 2000-12-14 | 2012-09-28 | Warner Chilcott Company | Cyclization process step in the making of quinolones and naphthyridines |
| AU2002305926A1 (en) | 2001-02-05 | 2002-10-08 | Exegenics Inc. | Cysteine protease inhibitors |
| JP3616628B2 (ja) | 2001-03-01 | 2005-02-02 | 塩野義製薬株式会社 | Ｈｉｖインテグラーゼ阻害活性を有する含窒素芳香族複素環化合物 |
| JP4518302B2 (ja) | 2001-03-19 | 2010-08-04 | 日本化薬株式会社 | 水溶性ジスアゾ化合物、水性ブラックインク組成物および着色体 |
| JP2002293745A (ja) | 2001-03-29 | 2002-10-09 | St Marianna Univ School Of Medicine | 慢性関節リウマチ治療剤 |
| JP3980842B2 (ja) | 2001-05-11 | 2007-09-26 | バブコック日立株式会社 | アンモニア含有排水の浄化装置および浄化方法 |
| JP2003065807A (ja) | 2001-08-29 | 2003-03-05 | Mitsubishi Electric Corp | プロセスデータのトレンド表示方法および装置 |
| JP3913037B2 (ja) | 2001-10-30 | 2007-05-09 | 三菱電機株式会社 | 赤外線検出器 |
| TW200300349A (en) | 2001-11-19 | 2003-06-01 | Sankyo Co | A 4-oxoqinoline derivative |
| EP2161258A3 (en) * | 2002-11-20 | 2010-04-07 | Japan Tabacco Inc. | 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
| JP2004253231A (ja) | 2003-02-20 | 2004-09-09 | Pioneer Electronic Corp | プラズマディスプレイパネル |
| MY134672A (en) * | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
| WO2005113509A1 (en) * | 2004-05-20 | 2005-12-01 | Japan Tobacco Inc. | Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
| EP3287130A1 (en) * | 2004-05-21 | 2018-02-28 | Japan Tobacco Inc. | Combinations comprising a 4-isoquinolone derivative and protease inhibitors |
| IN2014CN00532A (ja) | 2006-03-06 | 2015-04-03 | Japan Tobacco Inc | |
| RS54047B1 (sr) * | 2006-03-06 | 2015-10-30 | Japan Tobacco Inc. | Postupak za dobijanje jedinjenja 4-oksohinolina |
| TW200811153A (en) * | 2006-06-23 | 2008-03-01 | Japan Tobacco Inc | 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor |
| EA022099B1 (ru) * | 2006-09-12 | 2015-11-30 | Джилид Сайэнс, Инк. | Способы и интермедиаты для получения ингибиторов интегразы |
| AR068403A1 (es) | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
| MX2010002679A (es) * | 2007-09-12 | 2010-03-29 | Concert Pharmaceuticals Inc | Derivados de 4-oxoquinolina deuterados para el tratamiento de la infeccion por el virus de inmunodeficiencia humana. |
| WO2009089263A2 (en) | 2008-01-07 | 2009-07-16 | Ardea Biosciences Inc. | Novel compositions and methods of use |
| SI23420A (sl) | 2010-07-22 | 2012-01-31 | Institut "Jožef Stefan" | Kostni vsadki z večslojno prevleko in postopek njihove priprave |
| US11347056B2 (en) | 2018-08-22 | 2022-05-31 | Microsoft Technology Licensing, Llc | Foveated color correction to improve color uniformity of head-mounted displays |
| US11996736B2 (en) | 2018-08-23 | 2024-05-28 | Lg Innotek Co., Ltd. | Sensing device |
| WO2020040561A1 (ko) | 2018-08-24 | 2020-02-27 | 한온시스템 주식회사 | 차량용 공조장치 |
-
2003
- 2003-11-20 EP EP09169859A patent/EP2161258A3/en not_active Withdrawn
- 2003-11-20 AT AT03811532T patent/ATE443048T1/de active
- 2003-11-20 NZ NZ533641A patent/NZ533641A/en not_active IP Right Cessation
- 2003-11-20 SI SI200331707T patent/SI1564210T1/sl unknown
- 2003-11-20 EP EP10011216A patent/EP2272516A3/en not_active Withdrawn
- 2003-11-20 SK SK266-2004A patent/SK2662004A3/sk not_active Application Discontinuation
- 2003-11-20 BR BRPI0306214-7A patent/BRPI0306214B1/pt not_active IP Right Cessation
- 2003-11-20 EP EP03811532A patent/EP1564210B9/en not_active Expired - Lifetime
- 2003-11-20 WO PCT/JP2003/014773 patent/WO2004046115A1/ja not_active Ceased
- 2003-11-20 EP EP22158433.7A patent/EP4059923A1/en not_active Withdrawn
- 2003-11-20 DK DK03811532.5T patent/DK1564210T5/da active
- 2003-11-20 AU AU2003302029A patent/AU2003302029B8/en active Active
- 2003-11-20 PT PT03811532T patent/PT1564210E/pt unknown
- 2003-11-20 DE DE60329318T patent/DE60329318D1/de not_active Expired - Lifetime
- 2003-11-20 AR ARP030104286A patent/AR042095A1/es active IP Right Grant
- 2003-11-20 CZ CZ2004764A patent/CZ2004764A3/cs unknown
- 2003-11-20 CA CA2470365A patent/CA2470365C/en not_active Expired - Lifetime
- 2003-11-20 IL IL16254803A patent/IL162548A0/xx unknown
- 2003-11-20 MY MYPI20034478A patent/MY136173A/en unknown
- 2003-11-20 TW TW092132527A patent/TWI248928B/zh not_active IP Right Cessation
- 2003-11-20 TR TR2004/01663T patent/TR200401663T1/xx unknown
- 2003-11-20 PE PE2003001176A patent/PE20040840A1/es active IP Right Grant
- 2003-11-20 ES ES03811532T patent/ES2329240T3/es not_active Expired - Lifetime
- 2003-11-20 EP EP18166352.7A patent/EP3406596A1/en not_active Withdrawn
- 2003-11-20 US US10/492,833 patent/US7176220B2/en active Active
- 2003-11-20 KR KR1020047010082A patent/KR100665919B1/ko not_active Expired - Lifetime
-
2004
- 2004-06-08 ZA ZA2004/04537A patent/ZA200404537B/en unknown
- 2004-06-16 IL IL162548A patent/IL162548A/en active Protection Beyond IP Right Term
- 2004-07-02 MX MXPA04006553A patent/MXPA04006553A/es active IP Right Grant
- 2004-07-14 NO NO20043004A patent/NO327098B1/no not_active IP Right Cessation
-
2006
- 2006-06-05 US US11/446,128 patent/US8232401B2/en active Active
-
2009
- 2009-12-11 CY CY20091101301T patent/CY1110690T1/el unknown
-
2012
- 2012-06-20 US US13/528,688 patent/US20130172344A1/en not_active Abandoned
- 2012-07-03 AR ARP120102410A patent/AR087046A2/es unknown
-
2013
- 2013-07-12 LT LTPA2013018C patent/LTPA2013018I1/lt unknown
- 2013-11-07 HU HUS1300066C patent/HUS1300066I1/hu unknown
- 2013-11-07 NO NO2013015C patent/NO2013015I2/no unknown
- 2013-11-11 LU LU92307C patent/LU92307I2/fr unknown
- 2013-11-12 FR FR13C0061C patent/FR13C0061I2/fr active Active
- 2013-11-14 BE BE2013C063C patent/BE2013C063I2/fr unknown
- 2013-11-18 CY CY2013043C patent/CY2013043I1/el unknown
-
2014
- 2014-06-10 US US14/301,083 patent/US20150174117A1/en not_active Abandoned
-
2019
- 2019-05-10 US US16/409,728 patent/US20200101061A1/en not_active Abandoned
-
2022
- 2022-05-13 US US17/663,391 patent/US20230190730A1/en not_active Abandoned
- 2022-07-22 NO NO2022032C patent/NO2022032I1/no unknown